Cardiac transplantation now permits prolonged survival for some patients with otherwise fatal heart disease. 
years. Annual cardiac catheterization and clinical follow-up were performed to assess systolic cardiac function, coronary anatomy, and quality of extended rehabilitation. We found that among these long-term survivors, the left ventricular ejection fraction remained constant (0.59 + 0.08 one year postoperatively, 0.57 + 0.09 at most recent study, p = ns). Segmental Incomplete control of allograft rejection has inhibited the widespread use of biologic cardiac replacement to treat irreversible heart disease, but prolonged and useful survival for some patients has been achieved. The quality of cardiac function and lifestyle in these patients define our minimal expectations for the future of cardiac transplantation, and, furthermore, serve to illustrate the gap between our current ability to treat irreversible heart failure and the ideal treatment of this disorder. This studypresents long-term hemodynamic and clinical evaluation of patients who have survived cardiac transplantation at Stanford University Medical Center for five or more years. (Fig. 2) . The reason for this elevation of survival rate is illustrated in Figure 2 . Although the annual decrement in survival rates after the first year has remained constant, at approximately 5% per year, attrition during the first year has decreased from 51 + 5% to 37 + 4% (p < 0.01); this improvement reflects changes in early postoperative management. 11.12
Six patients in this analysis died between five and eight years after transplantation. Four patients developed severe graft coronary artery disease; one of these died after myocardial infarction, and three died within one year of transplantation (two of infection and one of disseminated lymphoma). 13 This distribution of fatal complications parallels the experience with all 92 patients who underwent coronary transplants more than five years ago. There were 22 late deaths among 46 patients who survived more than one year after transplantation. Of these deaths, 17 of the 22 (77%) were caused by graft atherosclerosis or infection. Late rejection caused death in only two patients surviving more than one year after transplantation.
Survival is a necessary but insufficient condition for evaluating transplantation as therapy for advanced organ failure. The quality of survival is equally important. Of 167.75 patient-years of follow-up, 143.5 (86%) were judged within the category of complete rehabilitation, as defined above. Sixteen of the 25 patients (64%) were gainfully employed throughout their postoperative course. An additional seven patients were classified as more than 50% rehabilitated. Three Total hospital days/patient-year 16.7 patients remained chronically disabled from infection (two patients) and corticosteroid-induced orthopedic complications (one patient). A summary of the periods of hospitalization and major complications is presented in Table 1 . There were 132 routine admissions to the hospital (0.79 hosp/ pt-yr) for annual evaluation (three-day admission). There were 122 nonroutine admissions to the hospital (0.73 hosp/patient-year). The average period of hospitalization was 13.7 ± 12.4 days. Infection accounted for more than half of these (66 of 122), and for an even larger proportion of hospital days. There were only 16 admissions to the hospital for late graft rejection episodes, thereby accounting for fewer than 0.1 hospitalizations per patient-year.
Cardiac Function
The results of clinical evaluation of cardiac function including physical, chest roentgenographic, and electrocardiographic examinations were generally unchanged in the absence of acute intercurrent complications. Average electrocardiographic sum voltage declined 14% throughout the entire period. Significant decreases (greater than 20% of first-year baseline values), however, occurred in 12 of the 25 patients. In no patient was there associated evidence of graft rejection at examination of a biopsy specimen. Biopsy specimen data are difficult to quantitate. However, in the absence of acute rejection, endomyocardial biopsy specimens were remarkably constant, showing only a slight increase in interstitial fibrosis in some patients.
Complete hemodynamic data were available in 21 of 25 (84%) long-term survivors. In three of these, the original baseline data were not available, and one patient has subsequently refused invasive follow-up investigation. Figure 3 compares left ventricular ejection fraction at the first annual cardiac catheterization with that obtained at the most recent study (5.4 ± 1.1 years after operation). The values 0.59 + 0.08 and 0.57 ± 0.09, respectively, were not significantly different. Discussion This study illustrates four points. First, extended survival after cardiac transplantation is possible for some patients with otherwise fatal heart disease. Second, the quality of survival is acceptable. Third, cardiac graft function may remain intact for prolonged periods. Fourth, the outstanding residual problems of cardiac transplantation are graft coronary atherosclerosis and complications associated with current immunosuppression.
The five-year survival rate in this early period of our experience with cardiac transplantation (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) was 27%. This is comparable with results reported for a similar period of renal transplantation. The Advisory Committee to the Renal Transplant Registry reported five-year survival rates with a functioning graft of 28.6-34.6%, between 1968 and 1970. 16 Since then, overall patient survival after renial transplantation has improved with early aggressive retransplantation or return to dialysis.17'18 Similarly, overall survival among cardiac transplant recipients has improved with refinements in early postoperative management. We expect that long-term survival after renal transplantation will generally exceed that of cardiac transplantation because of the additional option of prolonged mechanical support of renal function available to patients with end-stage renal disease, a facility that, as yet, has no analog for cardiac patients. This option has reduced the complexities of retransplantation and permitted control of infection in the absence of immunosuppression.
The quality of survival among long-term survivors of cardiac transplantation is acceptable. The patients presented in this report required fewer than two hospitalizations per year with a total average length of stay of 16.7 days. Eighty-six per cent of cumulative postoperative course of the total group could be designated within the category of full rehabilitation. With respect to work status, 64% of the long-term cardiac transplant recipients remained employed. This is similar to the work status of patients following coronary artery bypass operation.1'2'20 Similar data for rehabilitation after renal transplantation are limited, but Gutman and co-workers have recently summarized the physical activity and employment status of patients on maintenance dialysis. 19 They found that only 60% of nondiabetic patients on dialysis were capable of a level of physical activity beyond L.
i L--i that of caring for themselves. No mention of duration of dialysis was included, and it was presumably less than five years. Furthermore, these patients were not subjected to immunosuppression. Finally, we are encouraged by the stability of cardiac graft function in this group. This does not, however, lessen our awareness that current methods for immunosuppression fail to uniformly prevent graft atherosclerosis, and furthermore, account for the majority of complications and deaths that occur after heart transplantation. Recent developments, specifically, the availability of cyclosporin A,2 in immunosuppressive therapy after transplantation may ameliorate these problems and extend the benefits of prolonged survival to a larger number of patients with irreversible myocardial failure.
